PRAX, US74006W2070

PRAX stock gained 3 percent as Praxis disclosed employee awards

Published on 10/05/2026 at 09:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PRAX stock was last at USD 295.51 on October 2, 2026, after Praxis granted 3,478 shares to 14 employees. Q2 adjusted loss per share beat consensus by USD 0.80.

PRAX, US74006W2070, Illustration mit AI erstellt.

PRAX stock gained 3.00 percent to USD 295.51 on Nasdaq on October 2, 2026, while Praxis Precision Medicines (ISIN US74006W2070) disclosed a new employee equity award. The company granted restricted stock units covering 3,478 shares to 14 non-executive employees on October 1, according to StockTitan.

Employee awards add a small equity signal

The awards vest in four equal annual installments and are tied to continued employment, the company release reported on October 2, 2026. The grant is modest beside the company's market value, but it gives investors a precise update on hiring and potential future share dilution.

Praxis is developing central nervous system therapies through its Cerebrum small molecule platform and Solidus antisense oligonucleotide platform. Its portfolio includes four late-stage product candidates, according to the company's investor-relations profile dated September 3, 2026.

Q2 loss beat the consensus estimate

Praxis reported an adjusted loss of USD 2.87 per share for Q2/2026, compared with a consensus loss estimate of USD 3.67, a USD 0.80 improvement versus expectations, according to Investing.com. The finance results also show a Q2/2026 net loss of USD 83.72 million and operating loss of USD 96.904 million.

Cash and cash equivalents stood at USD 474.761 million on June 30, 2026, while operating cash flow was negative USD 77.542 million for Q2/2026. Those figures make the late-stage pipeline and the timing of regulatory decisions more important to the valuation than near-term revenue.

Analysts see a wide valuation spread

The consensus listed by Investing.com is Strong Buy from 19 analysts. The average 12-month price target is USD 643.58, with a high of USD 1,201.00 and a low of USD 188.00; the average target is 117.8 percent above the October 2 price.

JonesTrading analyst Justin Walsh maintained a Buy rating and raised his target from USD 441 to USD 534 on October 2, 2026, according to Moomoo.

PRAX remains below its yearly high

PRAX was last at USD 295.51 on Nasdaq on October 2, 2026, with a session range of USD 286.00 to USD 298.56. The 52-week range was USD 50.31 to USD 392.70, and volume reached 456,098 shares. The next earnings date listed by Investing.com is November 11, 2026.